Opinion
Video
Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission
Experts discuss the steps taken to ensure optimal T-cell persistence with chimeric antigen receptor (CAR) T-cell therapy, exploring the underlying mechanisms of toxicity and T-cell exhaustion and the advantages of fast off-rate kinetics, defining durable remission post CAR T-cell therapy, and sharing their views on the benefits and risks of approved CAR T-cell therapies for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Video content above is prompted by the following:
- What steps do you take to ensure the greatest T-cell persistence rate with CAR T-cell therapy?
- With respect to toxicity and T-cell exhaustion, please explore the underlying mechanisms and advantages of fast off-rate kinetics.
- In your opinion, what constitutes durable remission post CAR T- cell therapy?
- Please share your views on the benefits and risks of approved and available CAR T-cell therapies for the adult patient population with relapsed or refractory B-ALL.
Latest CME
View All
Video
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
May 14th 2025 - May 15th 2026
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
May 13th 2025 - Jun 18th 2025
online-activity
Video
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
May 9th 2025 - Jun 14th 2025
online-activity
Related Content
.jpg?fit=crop&auto=format)
